

# RARE DISEASES

PARTNERING WITH CLIENTS  
TO TRANSFORM THE LIVES OF  
PATIENTS WITH RARE DISEASES

Expertise working with  
over 20 different products



## Extensive experience

- Gorlin syndrome
- Spinal muscular atrophy
- Idiopathic pulmonary fibrosis
- Cutaneous T-cell lymphoma
- Lennox-Gastaut syndrome
- Multiple myeloma
- Cryopyrin-associated periodic syndromes
- Lysosomal storage diseases
- Paroxysmal nocturnal hemoglobinuria
- Angelman syndrome
- Hereditary angioedema
- Fragile X syndrome
- Ovarian cancer
- Gaucher disease



## Targeted treatments



## Vaccines



## Monoclonal antibodies



## Deep market knowledge



## Multichannel activities



## Patient involvement



## Publication strategy



Danicopan



Farletuzumab



# INFLAMMATORY DISEASE & IMMUNOLOGY

A PRINCIPAL AREA OF SPECIALISM

More than 400 years of combined experience across 20 different companies and 42 different products



Broad & deep experience in multiple disorders including:

- |                            |                               |
|----------------------------|-------------------------------|
| Inflammatory bowel disease | Osteoarthritis                |
| Psoriasis                  | Transplant rejection          |
| Rheumatoid arthritis       | Giant-cell arteritis          |
| Psoriatic arthritis        | Respiratory                   |
| Pain                       | Primary immunodeficiencies    |
| Ankylosing spondylitis     | Secondary immunodeficiencies  |
| Plaque psoriasis           | Actinic keratosis             |
| Lupus nephritis            | Idiopathic pulmonary fibrosis |



Targeted treatments




Monoclonal antibodies

Working in partnership with many clients across a broad range of deliverables:

- Commercial and medical expertise
- Strategy and delivery
- Medical education
- Symposia and scientific meetings

- KOL engagement
- Scientific platforms and lexicons
- Publication planning
- Design and branding



First-in-class JAK inhibitor across multiple indications



IL-23 Inhibitors



Anifrolumab